Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic Oncotherapy and Chromatin Biology.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HIST1H3A/Histone H3/H3C1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HIST1H3A (Histone H3.1) Recombinant Proteins (WT & Mutants like H3K27M, H3G34R) High purity (>95%), Endotoxin Controlled, Theoretical MW verified. E. coli expressed. |
View HIST1H3A Products |
| Gene Delivery | HIST1H3A Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and chromatin remodeling assays. |
View HIST1H3A Products |
| Benchmark Ab | Anti-HIST1H3A Recombinant Antibody Sequence-verified positive control for Western Blot, ChIP, and ELISA assays. |
View HIST1H3A Products |
| Validator | HIST1H3A siRNA Set Target-specific knockdown verification in human cell lines. |
View HIST1H3A Products |
| Related Target A | EZH2 Primary methyltransferase responsible for H3K27 trimethylation; key target in PRC2-mediated gene silencing. |
View EZH2 Products |
| Related Target B | HDAC1 Histone deacetylase regulating chromatin condensation and transcription; synergistic target with Histone H3 modifiers. |
View HDAC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant Specificity (e.g., H3K27M vs. WT H3) | Sequence-verified mutant recombinant proteins with precise single-point amino acid substitutions. |
| Post-Translational Modification (PTM) Interference | High-purity unmodified and modified histone panels strictly verified by Mass Spectrometry. |
| Lack of Controls | Clinical-grade recombinant benchmark antibodies included for assay calibration. |
| False Positives in Chromatin Assays | Sequence-specific validated siRNA sets included for target knockdown validation. |
Live HIST1H3A/Histone H3/H3C1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HIST1H3A/Histone H3/H3C1 therapeutics is intensifying, with major players shifting focus from traditional epigenetic small molecules to highly specific mutant-targeted immunotherapies and peptide vaccines. As first-generation histone modifier inhibitors reach the clinic, the next wave of R&D is targeting oncogenic histone mutations (oncohistones) such as H3K27M and H3G34R/V, which act as dominant negatives to reprogram the epigenome in pediatric gliomas and other refractory solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-T / Immunotherapy | Immatics, Adaptimmune | Diffuse Midline Glioma (DMG), Glioma | MHC-Peptide Binding Assays (Need sequence-verified mutant peptides/proteins) |
| Small Molecule Inhibitors | Epizyme (Ipsen), Novartis | Lymphoma, Epithelioid Sarcoma, Solid Tumors | Methyltransferase/Demethylase Screening (Need pure Histone H3 substrate) |
| Peptide Vaccines | University of Pittsburgh, Clinical Consortia | H3K27M-mutant Gliomas | Epitope Specificity Validation (Need high-purity mutant vs. WT proteins) |